SG11201501620QA - Bicyclic aza compounds as muscarinic m1 receptor agonists - Google Patents
Bicyclic aza compounds as muscarinic m1 receptor agonistsInfo
- Publication number
- SG11201501620QA SG11201501620QA SG11201501620QA SG11201501620QA SG11201501620QA SG 11201501620Q A SG11201501620Q A SG 11201501620QA SG 11201501620Q A SG11201501620Q A SG 11201501620QA SG 11201501620Q A SG11201501620Q A SG 11201501620QA SG 11201501620Q A SG11201501620Q A SG 11201501620QA
- Authority
- SG
- Singapore
- Prior art keywords
- muscarinic
- receptor agonists
- aza compounds
- bicyclic aza
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702330P | 2012-09-18 | 2012-09-18 | |
| US201361823606P | 2013-05-15 | 2013-05-15 | |
| PCT/GB2013/052442 WO2014045031A1 (fr) | 2012-09-18 | 2013-09-18 | Composés aza bicycliques utilisés comme agonistes du récepteur muscarinique m1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501620QA true SG11201501620QA (en) | 2015-04-29 |
Family
ID=49237505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501620QA SG11201501620QA (en) | 2012-09-18 | 2013-09-18 | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9266857B2 (fr) |
| EP (1) | EP2897948B1 (fr) |
| JP (2) | JP6204476B2 (fr) |
| CN (2) | CN104640851B (fr) |
| AU (2) | AU2013319989C1 (fr) |
| BR (1) | BR112015006029B1 (fr) |
| CA (1) | CA2883210C (fr) |
| DK (1) | DK2897948T3 (fr) |
| ES (1) | ES2602039T3 (fr) |
| HK (1) | HK1212328A1 (fr) |
| SG (1) | SG11201501620QA (fr) |
| WO (1) | WO2014045031A1 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831541B (zh) * | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
| CN104640851B (zh) * | 2012-09-18 | 2017-05-31 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| CA2938169C (fr) * | 2014-02-06 | 2022-03-15 | Heptares Therapeutics Limited | Composes d'aza bicyclique comme agonistes de recepteur muscarinique m1 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| JP6639651B2 (ja) * | 2015-09-04 | 2020-02-05 | ヤンセン ファーマシューティカ エヌ．ベー． | 疼痛のための治療化合物及びその合成 |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2017210545A1 (fr) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Modulateurs des canaux potassiques |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| RS64889B1 (sr) | 2016-10-26 | 2023-12-29 | Constellation Pharmaceuticals Inc | Inhibitori lsd1 i njihova medicinska upotreba |
| HUE057710T2 (hu) | 2017-01-23 | 2022-05-28 | Cadent Therapeutics Inc | Káliumcsatorna modulátorok |
| EP3625232B1 (fr) | 2017-05-19 | 2021-06-23 | Council of Scientific and Industrial Research | Méthanopyrido [2, 1-a]isoindolones substituées utilisées en tant que modulateurs de machr pour traiter diverses conditions pathophysiologiques associées et leur procédé de préparation |
| GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
| WO2019089676A1 (fr) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonistes du récepteur muscarinique m4 à l'acétylcholine |
| EP3732163A4 (fr) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | Antagonistes du récepteur muscarinique de l'acétylcholine m4 |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| AU2019336671A1 (en) | 2018-09-04 | 2021-02-18 | Contineum Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CR20220141A (es) * | 2019-10-09 | 2022-05-03 | Novartis Ag | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
| PE20221454A1 (es) | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |
| EP4322951A1 (fr) * | 2021-04-13 | 2024-02-21 | Pipeline Therapeutics, Inc. | Composé cristallin d'antagonistes des récepteurs muscariniques m1 de l'acétylcholine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032479A1 (fr) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Derives de phtalamidepiperidine, de phtalamidepyrrolidine, et de phtalamide-azepine, leur preparation, et leur utilisation comme agonistes(antagonistes) des recepteurs muscariniques |
| US7524852B2 (en) * | 2002-06-07 | 2009-04-28 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| JP2008501031A (ja) * | 2004-05-28 | 2008-01-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| WO2006105035A2 (fr) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs muscariniques |
| JP2009521483A (ja) * | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| US20090221567A1 (en) * | 2008-02-28 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 |
| US20130197027A1 (en) * | 2010-03-10 | 2013-08-01 | Craig Lindsley | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| CN106831541B (zh) | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
| CN104640851B (zh) * | 2012-09-18 | 2017-05-31 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
-
2013
- 2013-09-18 CN CN201380048192.7A patent/CN104640851B/zh active Active
- 2013-09-18 ES ES13766641.8T patent/ES2602039T3/es active Active
- 2013-09-18 EP EP13766641.8A patent/EP2897948B1/fr active Active
- 2013-09-18 BR BR112015006029-3A patent/BR112015006029B1/pt active IP Right Grant
- 2013-09-18 CN CN201710299209.6A patent/CN107098899B/zh active Active
- 2013-09-18 DK DK13766641.8T patent/DK2897948T3/en active
- 2013-09-18 WO PCT/GB2013/052442 patent/WO2014045031A1/fr active Application Filing
- 2013-09-18 JP JP2015531649A patent/JP6204476B2/ja active Active
- 2013-09-18 CA CA2883210A patent/CA2883210C/fr active Active
- 2013-09-18 SG SG11201501620QA patent/SG11201501620QA/en unknown
- 2013-09-18 AU AU2013319989A patent/AU2013319989C1/en active Active
- 2013-09-18 US US14/428,927 patent/US9266857B2/en active Active
-
2015
- 2015-12-22 HK HK15112602.8A patent/HK1212328A1/xx unknown
-
2016
- 2016-01-15 US US14/996,829 patent/US9669013B2/en active Active
-
2017
- 2017-05-15 US US15/595,107 patent/US9975890B2/en active Active
- 2017-06-22 AU AU2017204256A patent/AU2017204256B2/en active Active
- 2017-08-31 JP JP2017166513A patent/JP6438091B2/ja active Active
-
2018
- 2018-05-15 US US15/980,278 patent/US10259802B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015528489A (ja) | 2015-09-28 |
| US9266857B2 (en) | 2016-02-23 |
| AU2013319989A1 (en) | 2015-03-12 |
| US20160128996A1 (en) | 2016-05-12 |
| JP6438091B2 (ja) | 2018-12-12 |
| JP2018021057A (ja) | 2018-02-08 |
| AU2017204256B2 (en) | 2018-10-18 |
| AU2013319989C1 (en) | 2017-08-17 |
| CN107098899B (zh) | 2019-09-06 |
| US20170247369A1 (en) | 2017-08-31 |
| AU2013319989B2 (en) | 2017-03-30 |
| EP2897948A1 (fr) | 2015-07-29 |
| DK2897948T3 (en) | 2016-12-05 |
| CN104640851A (zh) | 2015-05-20 |
| EP2897948B1 (fr) | 2016-08-31 |
| JP6204476B2 (ja) | 2017-09-27 |
| ES2602039T3 (es) | 2017-02-17 |
| CN104640851B (zh) | 2017-05-31 |
| HK1212328A1 (en) | 2016-06-10 |
| CA2883210C (fr) | 2021-06-15 |
| CN107098899A (zh) | 2017-08-29 |
| US9669013B2 (en) | 2017-06-06 |
| US9975890B2 (en) | 2018-05-22 |
| WO2014045031A1 (fr) | 2014-03-27 |
| AU2017204256A1 (en) | 2017-07-13 |
| CA2883210A1 (fr) | 2014-03-27 |
| BR112015006029B1 (pt) | 2022-01-25 |
| US20150232443A1 (en) | 2015-08-20 |
| BR112015006029A2 (pt) | 2017-07-04 |
| US20180258085A1 (en) | 2018-09-13 |
| US10259802B2 (en) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212328A1 (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists m1 | |
| HRP20181499T1 (hr) | Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora | |
| HK1206722A1 (en) | New bicyclic derivatives | |
| HK1212984A1 (zh) | 咪唑並吡啶化合物 | |
| HK1201737A1 (en) | Muscarinic m1 receptor agonists | |
| HK1252279A1 (zh) | 5- ht3受體拮抗劑 | |
| IL232570B (en) | Bicyclic derivatives of dihydroisoquinoline-1-one | |
| EP2840076A4 (fr) | Composé bicyclique | |
| EP2670746A4 (fr) | Composés hétéroaryles bicycliques en tant qu'agonistes du récepteur gpr119 | |
| HK1206340A1 (en) | New bicyclic thiophenylamide compounds | |
| HK1205738A1 (en) | Bicyclic substituted pyrimidine compounds | |
| EP2874621A4 (fr) | Antagonistes des récepteurs aux minéralocorticoïdes | |
| GB201502644D0 (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
| EP2864332A4 (fr) | Composés imidazo bicycliques imminium en tant qu'agents anti-tumoraux | |
| GB201216373D0 (en) | Appetite-suppressant composition |